Multiple sclerosis, commonly referred to as MS, is a debilitating disease of the central nervous system. MS affects about 2.3 million people worldwide. Symptoms can range from tingling and numbness to blindness and paralysis. They can vary greatly from one patient to another, and sometimes even in the same… Read More
Scott Chan moved from China to the U.S. with family at the age of ten. He passed the rigorous entrance exam and attended the merit-based Stuyvesant High School, widely held to be best public school in New York City. He earned undergraduate degrees from New York University followed by an MBA degree from the Zicklin School of Business at Baruch College.
Shortly thereafter Scott partnered with Dr. Stephen Leeb on numerous financial publications. Today, he serves as the lead analyst for Real World Investing and The Complete Investor.
Mr. Chan is an avid baseball fan and enjoys outdoor activities in his spare time. A multicultural person, he reads Chinese and speaks fluent Mandarin and Cantonese Chinese.
Under Armour is a popular brand among athletes and active people. The company tried to expand too quickly and has paid a price for it. Can it stage a come back? Read More
Gilead has seen its stock price slide in recent years as sales of its hepatitis c drugs are falling sharply. Are better days ahead? Read More
When people say “penny stocks,” they usually don’t actually mean stocks that trade for pennies. The SEC, in fact, defines the term as stocks that trade below $5. However, we are about to look at a little-known stock that literally can be had for pennies per share. With a… Read More
BioPharmX is a penny stock that literally sells for pennies a share. However, a low price alone doesn't mean it's a compelling investment. Let's see if this biotech is a good buy for 2019. Read More
Verizon is one of those stocks that won't excite many people. Yet for conservative investors, the stock is as steady as they come. Read More
Celgene stock has been driven down to very low levels after a couple of pipeline disappointments in the past year. Is it a bargain or a value trap? Read More